Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study

doi:10.3748/wjg.v31.i42.110069

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 42

This Article

(65)

(69)

(0)

(11)

(1)

(864)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Nov 14, 2025; 31(42): 110069
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.110069

Table 1 Characteristics of patients before and after propensity score matching, n (%)

Characteristics	Before PSM (n = 219)				After PSM (n = 63)
Characteristics	Conventional (n = 198)	Early (n = 21)	P value	SMD	Conventional (n = 42)	Early (n = 21)	P value	SMD
Sex			0.854	0.044			0.366	0.246
Male	128 (64.6)	14 (66.7)			23 (54.8)	14 (66.7)
Female	70 (35.4)	7 (33.3)			19 (45.2)	7 (33.3)
Age, years
< 65	136 (68.7)	11 (52.4)			27 (64.3)	12 (57.1)
≥ 65	62 (31.3)	10 (47.6)			15 (35.7)	9 (42.9)
Median, IQR	60.00 (54.00, 65.25)	63.00 (58.50, 70.00)	0.118	0.221	62.50 (57.00, 68.25)	63.00 (58.50, 70.00)	0.890	0.043
BMI, kg/m²
< 23	154 (77.8)	14 (66.7)			30 (71.4)	14 (66.7)
≥ 23	44 (22.2)	7 (33.3)			12 (28.6)	7 (33.3)
Median, IQR	20.83 (18.83, 22.54)	22.27 (20.74, 24.14)	0.015	0.573	21.34 (18.00, 24.16)	22.27 (20.74, 24.14)	0.135	0.448
ECOG grade			0.174	0.305			0.858	0.048
0	65 (32.8)	10 (47.6)			19 (45.2)	10 (47.6)
1-2	133 (67.2)	11 (52.4)			23 (54.8)	11 (52.4)
Stage			0.367	0.220			0.668	0.117
Stage II	56 (28.3)	4 (19.0)			10 (23.8)	4 (19.0)
Stage III	142 (71.7)	17 (81.0)			32 (76.2)	17 (81.0)
PNI			0.819	0.049			1.000	< 0.001
Yes	182 (91.9)	19 (90.5)			38 (90.5)	19 (90.5)
No	16 (8.1)	2 (9.5)			4 (9.5)	2 (9.5)
LVI			0.597	0.128			0.445	0.214
Yes	171 (86.4)	19 (90.5)			35 (83.3)	19 (90.5)
No	27 (13.6)	2 (9.5)			7 (16.7)	2 (9.5)
Histology			0.381	0.105			0.271	0.393
Differentiated	84 (42.4)	11 (47.6)			28 (66.7)	11 (47.6)
Undifferentiated	114 (57.6)	10 (52.4)			14 (33.3)	10 (52.4)
Chemotherapy regimen			0.002				0.136
mFOLFOX-6	14 (7.1)	6 (28.6)		0.858	5 (11.9)	6 (28.6)		0.424
SOX	102 (51.5)	5 (23.8)		0.596	19 (45.2)	5 (23.8)		0.462
XELOX	82 (41.4)	10 (47.6)		0.123	18 (42.9)	10 (47.6)		0.094

PSM: Propensity score matching; SMD: Standardized mean difference; IQR: Interquartile range; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; PNI: Perineural invasion; LVI: Lymphovascular invasion; mFOLFOX-6: 5-fluorouracil plus calcium folinate plus oxaliplatin; SOX: Tegafur plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin.

Full Size Table

Citation: Lin L, Zhang P, Wang YY, Cai YF, Wen LB, Chen WP, Xiao YF, Li ZK, Liu GY. Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study. World J Gastroenterol 2025; 31(42): 110069
URL: https://www.wjgnet.com/1007-9327/full/v31/i42/110069.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i42.110069

Lin L, Zhang P, Wang YY, Cai YF, Wen LB, Chen WP, Xiao YF, Li ZK, Liu GY. Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study. World J Gastroenterol 2025; 31(42): 110069 [PMID: 41278157 DOI: 10.3748/wjg.v31.i42.110069]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.